![](https://img.medscapestatic.com/vim/live/professional_assets/medscape/images/thumbnail_library/gty_230331_doctor_asian_patient_talking_800x450.jpg)
'Too Scared' to Deviate: When to De-Escalate TNBC Treatment?
When Erin Reardon, MD, started the doxorubicin phase of her neoadjuvant chemotherapy, she was already convinced she had crossed the threshold into overtreatment for her stage II, node-negative triple-negative breast cancer (TNBC). The harsh chemotherapy …